Beukenhorst, Anna L. http://orcid.org/0000-0002-1765-4890
Koch, Clarissa M. http://orcid.org/0000-0002-7424-6009
Hadjichrysanthou, Christoforos http://orcid.org/0000-0001-6166-5899
Alter, Galit
de Wolf, Frank http://orcid.org/0000-0001-6264-2461
Anderson, Roy M. http://orcid.org/0000-0002-9528-3175
Goudsmit, Jaap
Funding for this research was provided by:
Leiden Laboratories
Article History
Received: 7 October 2022
Accepted: 7 January 2023
First Online: 4 February 2023
Declarations
:
: C.H., R.M.A. and F.d.W. have no relevant financial or non-financial interests to disclose. A.B., C.K., G.A. and J.G. have disclosed that they are employees of Leyden Laboratories with stock options in this company. Leyden Laboratories develops intranasal technologies to administer substances for prevention and treatment of respiratory infections and non-communicable diseases, and is currently not involved in vaccine development, production or distribution.